Literature DB >> 25877390

Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum.

S Hendrickx1, A Mondelaers, E Eberhardt, L Lachaud, P Delputte, P Cos, L Maes.   

Abstract

Although miltefosine (MIL) has only recently been positioned as a first-line therapeutic option for visceral leishmaniasis, field reports note an increasing trend in treatment failures. Study of laboratory selected MIL-resistant strains is needed in the absence of confirmed resistant clinical isolates. In contrast to promastigotes, experimental in vitro selection of MIL-resistance on intracellular amastigotes has not yet been documented. This study reports for the first time the selection of MIL-resistance in Leishmania infantum LEM3323, a strain which clearly shows active intracellular replication. Starting from the hypothesis that active multiplication may be essential in the resistance selection process; several other L. infantum strains were evaluated. Although strain LEM5269 showed only marginally lower intracellular multiplication, selection for resistance failed, as was also the case for several other strains showing poor or no intracellular replication. These results suggest that intracellular multiplication may not be an absolute prerequisite for the outcome of experimental in vitro MIL-resistance selection in clinical field isolates.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25877390     DOI: 10.1007/s00436-015-4460-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  16 in total

1.  Kala-azar elimination programme in India.

Authors:  G P S Dhillon; S N Sharma; Bindu Nair
Journal:  J Indian Med Assoc       Date:  2008-10

2.  Drug susceptibility of Leishmania infantum (syn. Leishmania chagasi) isolates from Brazilian HIV-positive and HIV-negative patients.

Authors:  Raquel Inocêncio da Luz; Gustavo A S Romero; Maria Elizabeth Dorval; Israel Cruz; Carmen Cañavate; Jean-Claude Dujardin; Tim Van Assche; Paul Cos; Louis Maes
Journal:  J Antimicrob Chemother       Date:  2011-01-11       Impact factor: 5.790

Review 3.  An update on the diagnosis and treatment of canine leishmaniosis caused by Leishmania infantum (syn. L. chagasi).

Authors:  Chiara Noli; Manolis N Saridomichelakis
Journal:  Vet J       Date:  2014-09-10       Impact factor: 2.688

4.  Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.

Authors:  S Hendrickx; G Boulet; A Mondelaers; J C Dujardin; S Rijal; L Lachaud; P Cos; P Delputte; L Maes
Journal:  Parasitol Res       Date:  2014-03-11       Impact factor: 2.289

5.  Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

Authors:  Suman Rijal; Bart Ostyn; Surendra Uranw; Keshav Rai; Narayan Raj Bhattarai; Thomas P C Dorlo; Jos H Beijnen; Manu Vanaerschot; Saskia Decuypere; Subodh S Dhakal; Murari Lal Das; Prahlad Karki; Rupa Singh; Marleen Boelaert; Jean-Claude Dujardin
Journal:  Clin Infect Dis       Date:  2013-02-20       Impact factor: 9.079

Review 6.  Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Authors:  Thomas P C Dorlo; Manica Balasegaram; Jos H Beijnen; Peter J de Vries
Journal:  J Antimicrob Chemother       Date:  2012-07-24       Impact factor: 5.790

7.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.

Authors:  Karin Seifert; F Javier Pérez-Victoria; Marianne Stettler; María P Sánchez-Cañete; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2007-07-12       Impact factor: 5.283

8.  In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Authors:  Marieke Vermeersch; Raquel Inocêncio da Luz; Kim Toté; Jean-Pierre Timmermans; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  Leishmania resistance to miltefosine associated with genetic marker.

Authors:  Sandrine Cojean; Sandrine Houzé; Djamel Haouchine; Françoise Huteau; Sylvie Lariven; Véronique Hubert; Florence Michard; Christian Bories; Francine Pratlong; Jacques Le Bras; Philippe Marie Loiseau; Sophie Matheron
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

10.  Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes.

Authors:  Juliana B T Carnielli; Hélida M de Andrade; Simone F Pires; Alexander D Chapeaurouge; Jonas Perales; Renata Monti-Rocha; Sílvio F G Carvalho; Leonardo P Ribeiro; Reynaldo Dietze; Suely G Figueiredo; Elenice M Lemos
Journal:  J Proteomics       Date:  2014-05-27       Impact factor: 4.044

View more
  12 in total

1.  Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility.

Authors:  M Van den Kerkhof; L Van Bockstal; J F Gielis; P Delputte; P Cos; L Maes; Guy Caljon; Sarah Hendrickx
Journal:  Parasitol Res       Date:  2018-08-23       Impact factor: 2.289

2.  Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.

Authors:  Sarah Hendrickx; Magali Van den Kerkhof; Dorien Mabille; Paul Cos; Peter Delputte; Louis Maes; Guy Caljon
Journal:  PLoS Negl Trop Dis       Date:  2017-05-15

Review 3.  Evaluating drug resistance in visceral leishmaniasis: the challenges.

Authors:  S Hendrickx; P J Guerin; G Caljon; S L Croft; L Maes
Journal:  Parasitology       Date:  2016-11-21       Impact factor: 3.234

4.  Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.

Authors:  Alberto Rastrojo; Raquel García-Hernández; Paola Vargas; Esther Camacho; Laura Corvo; Hideo Imamura; Jean-Claude Dujardin; Santiago Castanys; Begoña Aguado; Francisco Gamarro; Jose M Requena
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-04-13       Impact factor: 4.077

5.  Interferon Alpha Favors Macrophage Infection by Visceral Leishmania Species Through Upregulation of Sialoadhesin Expression.

Authors:  Lieselotte Van Bockstal; Dimitri Bulté; Magali Van den Kerkhof; Laura Dirkx; Dorien Mabille; Sarah Hendrickx; Peter Delputte; Louis Maes; Guy Caljon
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

6.  Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.

Authors:  S Hendrickx; D Bulté; M Van den Kerkhof; P Cos; P Delputte; L Maes; G Caljon
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-12-11       Impact factor: 4.077

7.  Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.

Authors:  Annelies Mondelaers; Maria P Sanchez-Cañete; Sarah Hendrickx; Eline Eberhardt; Raquel Garcia-Hernandez; Laurence Lachaud; James Cotton; Mandy Sanders; Bart Cuypers; Hideo Imamura; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Guy Caljon; Francisco Gamarro; Santiago Castanys; Louis Maes
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

8.  Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis.

Authors:  Lieselotte Van Bockstal; Jovana Sádlová; Hamide Aslan Suau; Sarah Hendrickx; Claudio Meneses; Shaden Kamhawi; Petr Volf; Louis Maes; Guy Caljon
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-09-10       Impact factor: 4.077

9.  Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.

Authors:  Sarah Hendrickx; Lieselotte Van Bockstal; Dimitri Bulté; Annelies Mondelaers; Hamide Aslan; Luis Rivas; Louis Maes; Guy Caljon
Journal:  Parasit Vectors       Date:  2020-02-22       Impact factor: 3.876

10.  In-depth comparison of cell-based methodological approaches to determine drug susceptibility of visceral Leishmania isolates.

Authors:  Sarah Hendrickx; Lieselotte Van Bockstal; Guy Caljon; Louis Maes
Journal:  PLoS Negl Trop Dis       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.